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Abstract
Background: The prognosis of patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC) is poor.
There is no standard treatment available. Emerging evidence suggests a major role for antiangiogenic treatment
modalities in EOC, in particular in combination with the metronomic application of low dose chemotherapy. The
novel, investigational oral antiangiogenic agent pazopanib targeting vascular endothelial growth factor receptor
(VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit is currently being studied in different tumour
types and is already used as first line therapy in recurrent renal cell carcinoma. A combined therapy consisting of
pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with
recurrent, pretreated EOC.
Methods/design: This study is designed as a multicenter phase I/II trial evaluating the optimal dose for pazopanib
(phase I) as well as activity and tolerability of a combination regimen consisting of pazopanib and metronomic
cyclophosphamide in the palliative treatment of patients with recurrent, platinum-resistant, pre-treated ovarian
cancer (phase II). The patient population includes patients with histologically or cytologically confirmed diagnosis
of EOC, cancer of the fallopian tube or peritoneal cancer which is platinumresistant or -refractory. Patients must
have measurable disease according to RECIST criteria and must have failed available standard chemotherapy.
Primary objectives are determination of the optimal doses for pazopanib (phase I) and the overall response rate
according to RECIST criteria (phase II). Secondary objectives are time to progression, overall survival, safety and
tolerability. The treatment duration is until disease progression or intolerability of study drug regimen (with a
maximum of 13 cycles up to 52 weeks per subject).
Discussion: The current phase I/II trial shall clarify the potential of the multitargeting antiangiogenic
tyrosinkinaseinhibitor GW 786034 (pazopanib) in combination with oral cyclophosphamide as salvage treatment in
patients with recurrent, pretreated ovarian cancer.
Trial registration: ClinicalTrials.gov: NCT01238770
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About 8,200 women a year in Germany develop a malig-
nant tumour of the ovary. The incidence of ovarian carci-
noma has remained unchanged in the last few decades [1].
With more than 6,000 deaths, it is the fifth highest cause
of cancer-related mortality in women [2]. Symptoms of
the disease usually develop at a very late stage. For this
reason about 70% of patients are already in an advanced
stage of the tumour at the time of diagnosis (FIGO III or
IV). Surgical tumour removal is the primary treatment.
Whether and to what extent residual tumour formation is
present postoperatively is the deciding factor in the subse-
quent prognosis for the patient. After surgery, chemother-
apy involving paclitaxel plus carboplatin is generally
indicated in the event of an initially advanced tumour
stage [3-5]. Despite improved surgical procedures and a
high primary response to chemotherapy, about 75% of
patients with advanced ovarian carcinoma develop a
tumour relapse and die from the disease [6].
Data from numerous preclinical and clinical trials sup-
port the assumption of VEGF/VEGFR and PDGFR as tar-
get molecules for the treatment of the ovarian cancer.
Angiogenesis is a critical pathway in the development
and progression of cancer. Therefore, identification and
development of novel agents with limited toxicity that
target mechanisms of tumor progression such as angio-
genesis is of high priority.
Metronomic chemotherapy, defined as the frequent
administration of low doses of cytotoxic chemotherapy at
frequent intervals, suppresses tumor growth in experimen-
tal models, possibly by inhibiting angiogenesis by stimulat-
ing the release of thrombospondin [7-9]. These
experimental findings are supported by a clinical trial
where encouraging activity with minimal toxicity was
observed in patients with breast cancer [10]. In 2007,
Samaritini and co-workers reported about cyclophospha-
mide “metronomic” chemotherapy for palliative treatment
of a young patient with advanced epithelial ovarian cancer.
They demonstrated that the progression-free survival time
on daily low dose oral cyclophosphamide treatment was
65 months without side effects [11]. Furthermore, in
experimental models, the combined use of metronomic
chemotherapy with antiangiogenic therapies demonstrates
marked inhibition of tumor growth [12-15].
Recent data have shown that the combination of beva-
cizumab and metronomic oral cyclophosphamide, has
encouraging activity in recurrent ovarian cancer [16-18].
Further studies of synergistical effects to cut off the
blood supply by combination of known anti-angiogenesis
agents with a lower dose of chemotherapy on a pro-
longed basis is warranted.
Pazopanib is an oral, angiogenesis inhibitor targeting
vascular endothelial growth factor receptor (VEGFR),
platelet-derived growth factor receptor (PDGFR) and c-
kit. VEGF and PDGF are growth factors critical to the
development and growth of blood vessels - a process
known as angiogenesis. Angiogenesis plays a pivotal role
in the growth and spread of several tumour types, with
VEGF and PDGF overexpression linked to multiple can-
cers including cancers of the liver, lung, breast, kidney,
bladder, ovaries, and colon [19-21]. By inhibiting VEGFR,
PDGFR, and c-kit pazopanib may stop or slow the rate of
tumour growth and development. Pazopanib is currently
being studied in a number of different tumour types; clin-
ical data are published in renal cell carcinoma (Phase III),
breast cancer, ovarian cancer, STS, NSCLC, cervical can-
cer and clinical trials are currently underway in other
solid tumours. It is being evaluated as a monotherapy, in
combination with targeted therapies and in combination
with cytotoxic chemotherapy. More than 2,000 patients
have been treated to date in clinical trials. Pazopanib
(under the tradename Votrient
®) has been licensed by
the FDA for the treatment of patients with advanced
renal cell carcinoma (RCC) on the 19
th of Oct 2009 and
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been given a positive opinion by the committee for pro-
prietary medicinal products (CPMP) at the European
Medicines Agency 19
th February 2010. Pazopanib (under
the tradename Votrient
®) has been licensed by EMA in
EU on the 14
th of June 2010 for the treatment of patients
with advanced renal cell carcinoma (RCC).
Pazopanib demonstrated manageable safety profile and
clinical activity in a phase I study including ovarian can-
cer tumor types [22]. Clinical efficacy of pazopanib
treatment has been seen in several Phase II/III studies,
including in renal cell cancer [23], soft tissue sarcoma
[24], breast [25], non-small cell lung cancer [26] and
cervical cancer [27]. Study VEG104450 provided proof-
of-concept data for pazopanib as monotherapy in ovar-
ian cancer. VEG104450 is a Phase II study of pazopanib
in subjects with ovarian, fallopian tube, or primary peri-
toneal cancers who had responded to first-line che-
motherapy and who were at high risk of clinical
recurrence (as evidenced by rising CA-125 levels). 36
subjects were enrolled, of which 21 (58%) have received
one prior chemotherapy regimen. Final results obtained
recently indicate the following: 11 out of 36 (31%) sub-
jects experienced a CA-125 response to pazopanib with
responses occurring shortly after start of pazopanib
administration (median time to response 29 days) with a
median duration of response of 113 days [28].
The current trial shall clarify the potential of the mul-
titargeting antiangiogenic tyrosinkinaseinhibitor GW
786034 (pazopanib) in combination with oral cyclopho-
sphamide as salvage treatment in patients with recur-
rent, pretreated ovarian cancer.
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Study design
This study is designed as a multicenter phase I/II trial
evaluating the optimal dose for pazopanib (phase I) as well
as activity and tolerability of a combination regimen con-
sisting of pazopanib and metronomic cyclophosphamide
in the palliative treatment of patients with recurrent, plati-
num-resistant, pre-treated ovarian cancer (phase II).
Study objectives
Primary Objectives
￿ Determination of the optimal dose for pazopanib
(phase I)
￿ Determination of the overall response rate according
to RECIST criteria/clinical benefit (stable disease or par-
tial response or complete response) (phase II) 12 weeks
after start of treatment
Secondary Objectives
￿ Time to progression (TTP) according to RECIST
criteria
￿ Overall survival
￿ Evaluation of CA125 tumour response
￿ Safety and tolerability
￿ Assessment of quality of life over time as defined by
EORTC-QLQ C 30 and Ovar 28 questionnaire
Trial organization
The PACOVAR trial has been designed by the study
initiators at the Department of Gynecology and Obstetrics
at the University of Heidelberg Medical School. The trial
is carried out as a multicenter trial under cooperation with
the Department of Gynecology and Obstetrics of the Uni-
versity of Tuebingen Medical School, the Department of
Gynecology and Gynecologic Oncology of Marienkran-
kenhaus Hamburg, the Department of Gynecology and
Obstetrics of the University of Homburg/Saar, the Depart-
ment of Gynecology and Obstetrics, Klinikum Hetzelstift
Neustadt, the Department of Gynecology and Obstetrics,
Klinikum Konstanz, the Department of Gynecology and
Obstetrics of the University of Mainz Medical School and
the Department of Gynecology and Obstetrics, Klinikum
Chemnitz.
Coordination
The overall coordination is performed by the Department
of Gynecology and Obstetrics at the University of Heidel-
berg Medical School. This department is also responsible
for the overall trial management, database management,
quality assurance including monitoring and reporting.
Investigators
The study investigators are experienced gynecolgic
oncologists. Patients will be recruited and treated by the
phycisians of the corresponding trial center.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Heidelberg, Germany
(AFmu-241/2010). This study complies with the Helsinki
Declaration in its recent German version, the Medical
Association code of conduct, the principles of Good Clini-
cal Practice (GCP) and the Federal Data Protection Act.
The trial will also be carried out in keeping with local legal
and regulatory requirements. The medical secrecy and the
Federal Data Protection Act will be followed. The http://
ClinicalTrials.gov Protocol ID is NCT01238770.
Patient selection
P a t i e n t sm a yb ei n c l u d e di nt h es t u d yo n l yi ft h e ym e e t
all the following criteria:
1. Subjects must provide written informed consent
prior to performance of study specific procedures or
assessments, and must be willing to comply with treat-
ment and follow up assessments and procedures
2. Female subjects > 18 years of age
3. Histologically or cytologically confirmed diagnosis
of: epithelial ovarian cancer which is platinum resistant
(relapse-free interval < 6 months of a platinum-contain-
ing primary or secondary platinum therapy) or platinum
refractory (progressive disease during primary or sec-
ondary platinum therapy), cancer of the fallopian tube,
peritoneal cancer. Definition of relapse: Demonstration
of measurable or non-measurable tumour according to
RECIST criteria by an imaging procedure (where applic-
able before relapse surgery) or increase in the tumour
marker CA-125 to twice the upper laboratory value of
normal for the hospital
4. Patients must have failed available standard che-
motherapy regimen (except if medically contraindicated
or refused by the patient)
5. Prior treatment with at least 2 chemotherapy regi-
mens in advanced tumor setting
6. Performance status ECOG 0-2
7. Adequate contraception
8. Adequate organ function as defined
9. Measurable disease according to RECIST criteria
10. Able to swallow and retain oral medication
11. A life expectancy of at least 12 weeks
Excluson criteria
Patients will be excluded from the study for any of the
following reasons:
1. Diagnosis of any second malignancy within the last 5
years, with the exception of basal cell or squamous cell
skin cancer or in situ carcinoma of the cervix uteri
2. History or clinical evidence of central nervous sys-
tem (CNS) metastases or
leptomeningeal carcinomatosis, except for individuals
who have previously-treated CNS metastases, are
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or anti-seizure medication for 6 months prior to first
dose of study drug. Screening with CNS imaging studies
(computed tomography [CT] or magnetic resonance
imaging [MRI]) is required only if clinically indicated or
if the subject has a history of CNS metastases.
3. Clinically significant gastrointestinal abnormalities
which might interfere with oral dosing
￿ Active peptic ulcer disease
￿ Known intraluminal metastatic lesion/s with sus-
pected bleeding
￿ Inflammatory bowel disease
￿ Ulcerative colitis, or other gastrointestinal condi-
tions with increased risk of perforation
￿ History of abdominal fistula, gastrointestinal per-
foration, or intraabdominal abscess within 28 days
prior to beginning study treatment
￿ Malabsorption syndrome
￿ Major resection of the stomach or small bowel
4. Any unstable or serious concurrent condition (e.g.,
active infection requiring systemic therapy)
5. Prolongation of corrected QT interval (QTc) > 480
msecs
6. History of any one or more of the following cardio-
vascular conditions within the past 6 months:
￿ Cardiac angioplasty or stenting
￿ Myocardial infarction
￿ Unstable angina
￿ Symptomatic peripheral vascular disease
￿ Coronary artery by-pass graft surgery
￿ Class II, III or IV congestive heart failure as
defined by the New York Heart Association (NYHA)
￿ History of cerebrovascular accident, pulmonary
embolism or untreated deep venous thrombosis
(DVT) within the past 6 months. Note: Subjects with
recent DVT who have been treated with therapeutic
anticoagulant agents (excluding therapeutic warfarin)
for at least 6 weeks are eligible
7. Macroscopic hematuria
8. Hemoptysis that is clinically relevant within 4 weeks
of first dose of study drug
9. Evidence of active bleeding or bleeding diathesis
10. Known endobronchial lesions or involvement of
large pulmonary vessels by tumor
11. Prior major surgery or trauma within 14 days prior
to first dose of study drug and/or presence of any non-
healing wound, fracture, or ulcer
12. Chemotherapy or radiation therapy within 2 weeks
prior to the first dose of study drug.
13. Biological therapy, hormonal therapy or treatment
with an investigational agent within 28 days or 5 half-
lives, whichever is longer prior to the first dose of study
drug.
14. Prior antiangiogenic therapy.
15. Is unable or unwilling to discontinue predefined
prohibited medications listed in the protocol for 14 days
or five half-lives of a drug (whichever is longer) prior to
Visit 1 and for the duration of the study
16. Any ongoing toxicity from prior anti-cancer ther-
apy that is > Grade 1 and/or that is progressing in
severity
17. Known immediate or delayed hypersensitivity reac-
tion or idiosyncrasy to drugs chemically related to
pazopanib
18. Psychological, familial, sociological, or geographical
conditions that do not permit compliance with the
protocol.
19. Pregnancy (for women of childbearing potential
absence to be confirmed by ß-hCG-test) or lactation per-
iod or missing contraception of women of childbearing
potential (Pearl-Index < 1, e.g. hormonal contraception
including the combined oral contraceptive pill, the trans-
dermal patch, and the contraceptive vaginal ring, intrau-
terine devices or sterilization) during treatment and for at
least 6 months thereafter
20. More than 3 different chemotherapy regimens in
advanced tumor setting
21. Uncontrolled hypertension
22. History of ischemic event (stroke, myocardial
infarction, unstable angina, TIA, symptomatic peripheral
vascular disease)
23. History or clinical evidence of thrombo-embolic
event
24. History of haemoptysis, cerebral, or clinically sig-
nificant gastrointestinal haemorrhage in the past 6
months
25. Active bleeding
26. Signs/Suspicion of intestinal obstruction
Statistical calculations for trial sample size
Phase I
The sample size of the phase I part is based on the need
to establish the MTD of pazopanib in combination with
cyclophosphamide. Dependent on the dose escalation, as
many as 18 patients may be treated.
Phase II
The primary endpoint of phase II is the quantification of
the responder-fraction (CR/PR) according to RECIST cri-
teria of patients with platinum-resistant recurrent, pre-
treated ovarian cancer who receive pazopanib and cyclo-
phosphamide after 12 weeks of therapy. For each patient
the objective response is determined. Complete and
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otherwise there is no response.
The sample size was determined by using Simon’s two
stage optimal design [29]. The optimal design is that
design which attempts to ensure that as few patients as
possible receive what appears to be an ineffective drug
at the end of Stage I for the given constraints. In order
to calculate the sample size the following hypothesis
was considered
H0: p ≤ 0.10 versus H1: p ≥ 0.30,
meaning that a response rate of at most 10% of the
new therapy would have no clinical relevance whereas a
r e s p o n s er a t eo fa tl e a s t3 0 %w o u l dl e a dt of u r t h e r
investigation of that therapy. Furthermore the signifi-
cance level will be set to 5% and the power to 90%
which leads to the following sample sizes and stop
criteria.
Table 1 shows the main statistical parameters of the
trial calculation.
The above mentioned numbers refer to the sample
size of the Full analysis set. Assuming 10% attrition and
non-evaluability, this enrolment should yield 39 patients
for analysis. Patients who discontinue participation in
the clinical study will not be replaced as attrition and
non-evaluability are already considered in the calcula-
tion of sample size.
Study Medication
Cyclophophamide
Cyclophosphamide is a nitrogen mustard alkylating agent,
from the oxazophorines group. Cyclophosphamide mus-
tard forms DNA crosslinks between (interstrand crosslin-
kages) and within (intrastrand crosslinkages) DNA strands
at guanine N-7 positions. This leads to cell death.
Exhibiting cytotoxic effects only after activation in the
liver, cyclophosphomid is called a prodrug. Cyclopho-
sphamide is converted by enzymes of the Cytochrome
P450 to active metabolites. The main active metabolite
is 4-hydroxycyclophosphamide, which exists in equili-
brium with its tautomer, aldophosphamide. Most of the
aldophosphamide is oxidised by the enzyme aldehyde
dehydrogenase (ALDH) to make carboxyphosphamide.
Therefore, cells with relatively large concentrations of
aldehyde dehydrogenase (ALDH) (e.g. earlyhaematopoe-
tic stem cells and megakaryocytes as well as stemcells of
the mucous membranes) are less sensitive to the toxic
effects of cyclophoshamid than cells with lower levels of
aldehyde dehydrogenase. This difference in metabolism
is the reason for the relatively low toxicity of bone mar-
row (as anaemia, thrombocytopenia and leukopenia) or
mucous membranes.
Pazopanib
Pazopanib is an, oral, angiogenesis inhibitor targeting vas-
cular endothelial growth factor receptor (VEGFR), plate-
let-derived growth factor receptor (PDGFR) and c-kit.
VEGF and PDGF are growth factors critical to the devel-
opment and growth of blood vessels - a process known as
angiogenesis. Angiogenesis plays a pivotal role in the
growth and spread of several tumour types, with VEGF
and PDGF overexpression linked to multiple cancers
including cancers of the liver, lung, breast, kidney, bladder,
ovaries, and colon. By inhibiting VEGFR, PDGFR, and c-
kit pazopanib may stop or slow the rate of tumour growth
and development. Pazopanib is currently being studied in
a number of different tumour types; clinical trials are cur-
rently underway in renal cell carcinoma (Phase III), breast
cancer, ovarian cancer, STS, NSCLC, cervical cancer and
other solid tumours. It is being evaluated as a monother-
apy, in combination with targeted therapies and in combi-
nation with cytotoxic chemotherapy. More than 2000
patients have been treated to date in clinical trials. Pazopa-
nib (under the tradename Votrient
®) has been licensed by
the FDA for the treatment of patients with advanced renal
cell carcinoma (RCC) on the 19
th of Oct 2009 and is on
the market in the US. In the EU, pazopanib has been given
a positive opion by the committee for proprietary medic-
inal products (CPMP) at the European Medicines Agency
19
th February 2010. Pazopanib (under the tradename
Votrient
®) has been licensed by EMA in EU on the 14
th of
June 2010 for the treatment of patients with advanced
renal cell carcinoma (RCC).
Adverse events
Cyclophosphamide
The most common dose-limiting toxicity of cyclopho-
sphamide is myelosuppression.
Under therapy with Endoxan
® (trade name of cyclo-
phosphamide) the following, mostly reversible side
effects may occur dosisdependently. As a consequence,
in a metronomic low-dose application all stated adverse
events are seldom:
Table 1 Main statistical parameters of the trial
calculation
Parameter
p0 10%
p1 30%
a 5%
b 10%
Number of patients
Stage I 18
Stage II 17
Rejection of therapy
Stage I 0 - 2 responder among 18 patients
Stage II 0 - 6 responder among 35 patients
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cytopenia, thrombocytopenia and anaemia in different
grades of severity. Common: leukocytopenia with or
without fever and the risk of secondary (to some extend
life threatening) infections, thrombocytopenia, enhanced
risk of bleeding
Gastro-intestinal (stomach and bowel) disorders Com-
mon: Nausea, vomiting, anorexia, diarrhea, obstipation
and stomatitis.
Uncommon: Haemorraghic colitis and ulceration of
the oral mucosa.
Renal and urinary disorders Common: Haemorraghic
cystitis, micro-haematuria, macrohaematuria.
Hepato-biliary disorders Uncommon: Increase in
SGOT, SGPT, gamma-GT, alcalic phosphatase, bilirubin.
Cardiac, respiratory, thoracic and mediastinal disor-
ders Following high doses of cyclophosphamide (120-240
mg/kg body weight: Secondary cytostatics-induced cardio-
myopathy (arrhythmia, ECG alterations, LVEF alterations
(e.g. myocardial infarction). Following conventional doses
of cyclophosphamid: Uncommon: Pneumonitis, interstitial
pneumonia, chronic interstitial lung firbrosis.
Secondary malignancies As generally described for cyto-
static therapy, for the application of cyclophosphamide
risc of secondary malignancy or prestages are described as
long-term complications due to therapy. Enhanced risk
exists e.g. for developement of carcinoma of urinary tract
as well as for myelodysplastic alterations up to acute
leukaemia.
Metabolic disorders In particular in patients with non-
hodgkin-lymphoma or leukaemia, increased levels of uric
acid may occur due to a rapid-tumor-lysis syndrome.
Other side effects Common: Alopecia (reversible).
Also alterations of pigment of palm of hand, finger nails,
sole of foot as well as skin inflammation and mucositis are
reported.
Pazopanib
In clinical trials, pazopanib has been well tolerated. Its
most common side effects in clinical trials to date include
diarrhea, hypertension, fatigue, nausea, anorexia, vomit-
ing, hair depigmentation, rash and abdominal cramps.
More specifically, in the phase I clinical trial in patients
with solid tumors, the most common adverse events (all
grades) were hypertension (33%) diarrhea (33%), hair
depigmentation (32%), nausea (32%), anorexia (25%), fati-
gue (24%) andvomiting (17%), [22]; hypertension and
hair depigmentation were indicative of VEGFR and c-kit
modulation.
In the clinical trial in patients with gynecological can-
cers, fatigue, hypertension, diarrhea, ALT/AST elevation,,
vomiting, abdominal pain and nausea were the most com-
mon side effectsGrade 3 adverse events were fatigue
(11%), GGT elevation (11%), diarrhea (8%), ALT elevations
(8%), Hypertension (3%), AST elevation (3%), Abdominal
pain (3%), Constipation (3%), Headache (3%) and Ascites
(3%). Only one grade 4 adverse event (peripheral edema)
was reported; [28].
Investigation schedule
Therapy indication
This study is a prospective open-label, non-randomized
multicenter phase I/II trial in order to determine overall
response rate of patients with platinum-resistant or
refractory recurrent, pretreated epithelial ovarian cancer.
Pre-therapeutic examinations
Patients eligible for the study will initially be screened
for their suitability to take part in the study. Patients
not included in the study should be recorded in a
screening log, with a statement of the reasons for their
non-participation. Informed consent must be obtained
prior to performance of any study-specific procedure. If
not noted otherwise, the baseline examinations should
be performed within 4 weeks before start of treatment:
￿ Previous history, physical examination including
weight control and vital signs, ECG (ECG no more
than 21 days old on inclusion in the study), gynaeco-
logical examination
￿ Assessment of general well-being according to
ECOG within 7 days prior to start of study drug
￿ Documentation of measurable and non-measurable
tumour lesions. For radiological disease assessments,
CTs and MRIs are acceptable and are used inter-
changeably below; however, for each individual subject
the same one method must be used throughout the
study.
￿ CA-125 tumour marker (determined not more
than 7 days before start of treatment). Two pretreat-
ment values at least twice the upper limit of normal
are required for an evaluation of the response by
means of CA-125.
￿ Blood count, blood chemistry obligatory (within 7
days before inclusion in the study and within 4 weeks
before start of treatment): Haematocrit, haemoglobin,
white blood cell (WBC) count, red blood cell (RBC)
count, lymphocyte count, neutrophil count, platelet
count, aPTT and PT-INR, SGOT, SGPT, alkaline
phosphatase, bilirubin (total), urea (blood urea nitro-
gen), creatinine, creatinine clearance (CrCl) calculated
using Cockcroft and Gault formula, calcium, potas-
sium, sodium, magnesium, glucose, lactate dehydro-
genase (LDH), albumin, amylase, TSH, free T4, urine
dipstick for protein
￿ Women of childbearing potential must have a
negative pregnancy test (HCG in urine/serum) not
more than 7 days old on start of treatment.
Quality of life (EORTC-QLQ C 30 and Ovar 28)
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Phase I
Cyclophosphamide Pazopanib
Dose level I 50 mg/day 400 mg/day
Dose level II 50 mg/day 600 mg/day
Dose level III 50 mg/day 800 mg/day
Within the phase I part of the trial, doses of cyclopho-
sphamide and pazopanib are assigned at registration
according to the dose escalation scheme following
Goodman et al. [30].
Before embarking on the phase II part of the study,
phase I safety data will be reviewed. If there is a dose-
limiting toxicity at dosage level I, then the phase II part
of the study will not be initiated.
Treatment Regimen Phase II
Cyclophosphamide 50 mg daily orally.
Pazopanib 400, 600 or 800 mg daily orally.
T h ed o s ef o rt h ep h a s eI Ip a r to ft h et r i a lw i l lb e
based on the MTD of phase I.
Duration of treatment
A treatment cycle consists of 4 weeks. Patients will
receive up to 13 cycles (52 weeks) of cyclophosphamid
with pazopbanib. Patients continue on treatment until
until disease progression or intolerability of study drug
regimen or as long as no other therapy is indicated.
Tumour assessment and response
Tumour Response According to RECIST Criteria
Target lesions will be measured in a dimension using the
longest diameter. The tumour response will be investi-
gated every 12 weeks during treatment phase and every
three months during Follow-Up or on signs of tumour
progression. The same investigational method must be
used throughout. Any partial or complete remission must
be confirmed after at least 4 weeks. Complete response
(CR): Disappearance of all lesions and appearance of no
new lesions. Partial response (PR): At least a 30% decrease
in the sum of the longest diameter of target lesions. No
new lesions may occur or individual lesions progress. Pro-
gressive disease (PD): At least a 20% increase in the total
of the longest diameters of target lesions (as reference to
the smallest sum recorded since the treatment started) or
the appearance of new lesions. If the marker lesion disap-
pears and the progression of a lesion or the appearance of
new lesions is observed elsewhere at the same time, this is
also documented as a progressive disease.
Stable disease (SD): Neither a partial nor a complete
response in the absence of progression. Confirmation of
response is required in the case of CR and PR at a mini-
mum interval of not less than 4 weeks. In the case of
SD, measurements must have met the SD criteria at
least once after study entry at a minimum interval of
not less than 6-8 weeks.
CA-125 Tumour Response
Based on the CA-125 response criteria of the GCIG
[31], modified according to Levy et al. [32], the follow-
ing definitions are employed:
Complete response (CR): The CA-125 value of two
determinations falls to within the normal range for at
least 4 weeks. Partial response (PR): A decrease in the
CA-125 value by ≥ 50% in 2 determinations for at least
4 weeks. Progressive disease (PD): An increase in CA-
125 to values ≥ 125% of baseline value 2. At the same
time, tumour lyses must be excluded clinically. Stable
disease (SD): Patients to whom none of the previous cri-
teria apply for at least 8 weeks.
Response unevaluable: Defined as no new evaluation
of the tumour by the determination of CA-125 after the
beginning of the study therapy for reasons not associated
with the symptoms or signs of the disease.
After a complete remission is obtained, a (secondary)
progression is defined as an increase in CA-125 to ≥ 125%
of the upper limit of normal. After a partial remission or
stable disease, a progression is present if the CA-125
increases to more than 125% of the nadir. The flow chart
for the determination of CA-125 and for assessing the
response
Assessment of safety
Adverse Events
The investigator is responsible for documenting all adverse
events that occur during the study. Adverse events are all
harmful, pathological or unintentional changes in anato-
mical, physiological or metabolic functions observable in
the form of physical signs, symptoms and/or changes in
laboratory values that occur during any part of the clinical
trial, irrespective of whether there is any relationship to a
medication. This also includes a deterioration in preexist-
ing diseases or events, diseases that occur in the interven-
ing period, changes of medication or a significant
deterioration in the disease studied. Expected daily varia-
tions in the disease under study that do not represent a
clinically significant deterioration should not be consid-
ered an adverse event.
Causal Assessment
The investigator should make every effort to elucidate
any adverse event and where necessary to assess its rela-
tionship to the study medication. The causal relationship
should be assessed on the basis of the following cate-
gories: no relationship, relationship unlikely, relationship
suspected (justified suspicion) and relationship probable.
The degree of certainty of the relationship between
adverse event and drug is determined by how well the
event can be explained by the following ftors: (1) known
pharmacological properties, (2) comparable reactions
observed previously with the drug or another member of
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monly described in the literature as drug-related, (4) a
chronological relationship between the event and drug
intake, disappearance on withdrawal or recurrence on re-
institution of the drug.
Follow-up
Follow-up investigations will be done every 3 months
over 24 months with the aim of determining the time of
tumour progression.
The following examinations will be performed every 3
months after end of treatment
￿ Survival status
￿ Medical history, physical examination
￿ Assessment of ECOG performance
￿ Determination of tumour progression
￿ CA-125 tumour marker
￿ Further anticancer treatment
￿ Quality of life (EORTC-QLQ C 30 and Ovar 28)
The follow-up information can be collected by phone.
Monitoring
Study monitoring is undertaken by monitors appointed
by ALCEDIS GMBH, Giessen, Germany. The responsi-
ble monitor will be allowed, on request, to inspect the
various records of the trial (Case Report Forms and
other pertinent data). Due to the electronic documenta-
tion system checks for range and plausibility are per-
formed during data entry. The monitor gets an access to
read the data only. In line with ICH GCP guidelines,
monitoring will include verification of data entered in
the eCRF against original patient records. This verifica-
tion will be performed by direct access to the original
subject records, and the Sponsor guarantees that patient
confidentiality will be respected at all times. Participa-
tion in this study will be taken as agreement to permit
direct source data verification.
Discussion
Epithelial ovarian cancer remains the most lethal gyne-
cologic malignancy [1-4,6]. In recurrent, advanced dis-
ease, treatment options are limited after failure of
platinum compounds and new investigational strategies
are highly needed [1-6].
There is increasing evidence that antiangiogenic tar-
geted therapies show promising efficacy in the palliative
systemic treatment of the disease. In particular bevacizu-
mab, combined with metronomically administered cyclo-
phosphamide was shown to be beneficial [16-18]. It is the
aim of this trial to elucidate the therapeutic potential of
the new antiangiogenically active multityrosinekinase
inhibitor pazopanib combined with metronomically
orally taken low dose cyclophosphamide in patients with
advanced EOC. Once the best tolerable dosage has been
found within the first phase I-part of the trial, a subse-
quent phase II-investigation shall clarify the activity and
tolerability of the schedule in a larger number of patients.
If a combination of pazopanib and metronomic low
dose cyclophosphamide can be shown to be active and
feasible in intensively pretreated patients with advanced
EOC this would mark a major clinical benefit as a new,
additive and presumably well mangeable oral treatment
option could be add to the existing therapy concepts
and give time and quality of life to our patients.
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